Research programme: antisense oligonucleotide therapeutics - GondolaBio/n-Lorem Foundation
Latest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator n-Lorem Foundation
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inborn genetic disorders